Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Crinetics Pharmaceuticals excels in 2023 with promising pipeline advancements

Crinetics Pharmaceuticals had a successful year in 2023, with promising results from their lead candidate, paltusotine, in acromegaly and carcinoid syndrome, supported by a strong financial position and progress in key clinical trials.
While facing challenges in response rates and drug positioning, Crinetics remains focused on advancing their pipeline, exploring new treatment pathways, and optimizing drug characteristics for efficacy and safety.
Opportunities lie in expanding the therapeutic portfolio, upcoming data releases, and engagement at industry events to drive awareness, investor confidence, and potential market growth for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals reports positive Q1 results and pipeline advancements

Crinetics Pharmaceuticals showcased positive clinical results and a strong financial position in Q1 2024, with plans for Phase III studies and NDA filings.
The company's focus on injectable depot therapies addresses treatment burden challenges, while questions raised during the call highlight areas for further development.
Anticipation for future updates from the pipeline and opportunities for market expansion through strategic relationships position Crinetics for potential growth.
Despite facing a high cash burn rate, Crinetics Pharmaceuticals' progress in key therapeutic areas and financial strengthening provide a foundation for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--Craig Gordon, MD, Chief Executive Officer of GordonMD® Global Investments LP, announced today that his firm has jointly invested in a private placement financing for Radionetics Oncology. Radionetics Oncology, a clinical stage pharmaceutical company spun out of Crinetics (Nasdaq: CRNX) in 2021, focuses on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. GordonMD® joins Frazier Healthcare,.

GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology

SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on October 10, 2023, the Compensation Committee of Crinetics' Board of Directors granted non-qualified stock option awards to purchase an aggregate of 619,100 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Denison Mines

Globalstar

Lithium Americas Corp

Pagaya Technologies Ltd

Solid Power

SoFi Technologies

As economic and stock market uncertainty looms, you may think at first that now is not a great time to be dabbling in speculative stocks. Yet, while the broad market may be experiencing turbulence right now, there are several stocks benefiting from company-specific catalysts that outweigh the macro issues.

7 Speculative Stocks Set to Explode Higher

Crinetics (CRNX) surges 69.6% in a month due to encouraging results from its late-stage study, paltusotine, in patients with acromegaly who were switching from current standard-of-care treatment.

Crinetics (CRNX) Stock Surges 70% in a Month: Here's Why

SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-28, 2023.

Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023

Crinetics Pharmaceuticals' lead candidate could be commercialized soon. It'll have a hard time gaining market share quickly if it gets approved for sale.

Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?

Crinetics Pharmaceuticals announced positive late-stage trial data for its acromegaly drug this week. If approved, analysts think this oral therapy could rake in nearly half a billion in annual sales at peak.

Why Crinetics Pharmaceuticals Stock Soared This Week

Crinetics focuses on treatments for rare endocrine-related diseases and cancers. The company had only $264.5 million in cash as of the second quarter.

Why Shares of Crinetics Pharmaceuticals Are Jumping Monday

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock is surging today, last seen up 72.7% to trade at $27.58 at last check, after the late stage trial for its experimental drug paltusotine to treat a rare hormonal disorder was successful.

Pharma Stock Eyes Best Day Ever on Successful Trial

Crinetics Pharmaceuticals Inc shares jumped more than 60% in pre-market trading on Monday after the clinical stage pharmaceutical company announced that its experimental treatment for a rare hormonal disorder exceeded analyst forecasts in a Phase 3 trial.  Crinetics said 83% of patients on its experimental drug paltusotine were able to maintain growth-factor levels, compared to 4% who were receiving the placebo.

Crinetics Pharmaceuticals stock soars on hormonal drug study results

Crinetics Pharmaceuticals (NASDAQ: CRNX ) stock is on the rise Monday after the company announced positive clinical trial results. According to a press release from the company, its Phase 3 PATHFNDR-1 clinical trial was able to meet all of its primary and secondary endpoints.

Why Is Crinetics Pharmaceuticals (CRNX) Stock Up 64% Today?

Shares of Crinetics Pharmaceuticals Inc. CRNX, -1.18% gained 65% premarket on Monday after the company announced positive results from a late-stage study of paltusotine, its investigational treatment for acromegaly. The phase 3 trial met the primary endpoint and all secondary endpoints and no serious or severe adverse events were reported in patients receiving paltusotine for acromegaly, a rare disease that occurs when the body produces too much growth hormone.

Crinetics Pharmaceuticals shares surge 65%, analysts raise price target after acromegaly treatment results

83% of Participants on Paltusotine Maintained IGF-1 ≤1.0 xULN vs. 4% on placebo (p

Crinetics' Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

Shares of Crinetics Pharmaceuticals Inc. CRNX, gained more than 4% premarket on Thursday after Oppenheimer analysts initiated coverage of the shares with an outperform rating, calling Crinetics ‘drug hunters in their zone.' Crinetics focuses on developing treatments for rare endocrine diseaess, an area where current drugs' risk-benefit tradeoffs “leave much room for improvement, or approved options are outright lacking,” the analysts wrote in a note Wednesday.

Crinetics Pharmaceuticals shares rise as analysts see ‘drug hunters in their zone'

Crinetics Pharmaceuticals, Inc. is my latest long position. The company has two Phase 3 data releases for Paltusotine in treating acromegaly over the next 7-8 months. Acromegaly is a disorder caused by excess levels of growth hormone, and current treatments have side effects.

Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly

Crinetics Pharmaceuticals has shown a significant increase in R&D and administrative expenses, leading to a widening net loss trajectory. The company's primary revenue source is the drug paltusotine, which has shown promising results in the treatment of acromegaly. Crinetics has a robust product pipeline, including potential treatments for Cushing's disease and neuroendocrine tumors.

Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At ENDO

Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3 PATHFNDR-2 Study with Topline Data Expected in 1Q 2024 CRN04777 Development Suspended Company Hosting KOL Webinar on Acromegaly Treatment Landscape Today at 12:00 pm ET SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.  (Nasdaq: CRNX) today reported financial results for the second quarter ended June 30, 2023. “The PATHFNDR program for acromegaly continues to progress as expected.

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire window.initGradientEffect = function () { } document.addEventListener('DOMContentLoaded', function () { const extendedTableZoomElements = document.querySelectorAll('.extended-table-zoom'); if (extendedTableZoomElements && extendedTableZoomElements.length > 0) { window.Stickyfill.add(extendedTableZoomElements); } const socialMediaSideBarContainerElement = document.querySelectorAll('.social-media-side-bar-container'); if (socialMediaSideBarContainerElement && socialMediaSideBarContainerElement.length > 0) { window.Stickyfill.add(socialMediaSideBarContainerElement); } }, false); window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-ERWPGTJ5X8'); Accessibility: Skip TopNav // used in ui component window.pnrApplicationSettings = { Application:"pnr", SelectedLocale: 'en-US', PnrHostUrl: 'https://www.globenewswire.com', IsAuthenticated: false, ContextUser: '', ApplicationUrl: 'https://www.globenewswire.com', PageContext: '', SubscriptionId: 0, SubscriptionName: '', ArticleLogoUrl: '', ArticleHeadline: '', IsMobileVersion: 'False' === "True" ? true : false, HideLanguageSelection : false, NewsSearchHeading: '', ArticleMediaAttachments: [], AuthSessionExpirationMinutes: '0', AppLogoUrl: 'https://www.globenewswire.com/content/logo/color.svg', ReaderForgotPasswordUrl: 'https://pnrlogin.globenewswire.com/en/reset/confirmresetpassword', ReaderRegisterUrl: 'https://pnrlogin.globenewswire.com/en/register', IsQuickSignInEnabled: true, ReaderAccountBaseUrl: '' }; We're sorry, you encountered a page that doesn't exist.

Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly

Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship

Crinetics to Highlight Broad Pipeline at ENDO 2023

Crinetics Pharmaceuticals, Inc. is developing an oral nonpeptide drug for acromegaly patients. The drug is claimed to have advantages over injectable and oral somatostatin analogues.

Crinetics Pharmaceuticals And Its Value Proposition In Acromegaly

Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.73 per share a year ago.

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the first quarter ended March 31, 2023.

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Crinetics Pharmaceuticals, Inc. (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q1 Earnings Expected to Decline

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -2.44% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates

SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.

News for Crinetics Pharmaceuticals Inc Stock (CRNX)